Upcoming catalysts, page-154

I am slightly concerned with the poor US study results that were submitted to FDA in comparison to Aus and EU results. Are we using the same results from Oct 2018 that spooked the market and plunged the SP by 60%?
Is there a small/large chance of RAP not getting FDA clearance due to the weak results?
It'd be great if any long term holders can clarify my understanding, am i missing something that gives some of the holders here confidence for FDA clearance?

It has taken several years for RAP to come to this stage and many great milestones were achieved, but the biggest one is yet to come so i really hope FDA gives green light and all LT holders reap the rewards.